- Eli Lilly’s rheumatoid arthritis drug baricitinib, sold under the brand name Olumiant, prevented 1 death for every 6 patients on a ventilator in a phase 3 clinical trial.
- The FDA revised its emergency use authorization for Regeneron’s COVID-19 antibody cocktail of casirivimab and imdevimab, allowing the treatment to be used as a post-exposure prophylaxis for COVID-19 in individuals who are at high risk for progression to severe COVID-19.
- Bamlanivimab or casirivimab-imdevimab, two monoclonal antibodies, were effective in preventing hospitalization among high-risk patients with COVID-19 when administered separately in a real-world study.
- Gilead’s remdesivir may be associated with longer hospital stays for COVID-19 patients, even after they have recovered, so that they can finish the treatment course, a study suggested.
- The antibiotic azithromycin didn’t reduce the risk of hospitalization, respiratory failure or death in COVID-19 patients in a clinical trial.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
